Search - tctmd.com

Displaying 161 - 180 of 3616

Sort: Relevancy | Date

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Have Contemporary DES Narrowed the Gap With CABG in Multivessel Disease? From BEST to SYNTAX II and Beyond

Presenter: Dean J. Kereiakes, Pieter C. Smits, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Bryan Williams

October 30, 2016

Presentation TCT 2016

Comparative DES Outcomes: What Have We Learned From the SCAAR Registry? Update on Recent New Generation DES

Presenter: Dean J. Kereiakes, Pieter C. Smits, Stefan K. James

October 30, 2016

Presentation TCT 2016

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Presenter: Peter Juni, E. Magnus Ohman, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

Presenter: Dean J. Kereiakes, Pieter C. Smits, Lisette Okkels Jensen

October 30, 2016

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Roxana Mehran, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Thomas Pilgrim

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: From Nobori to Ultimaster Biolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Shigeru Saito

October 30, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: BioMatrix Biolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Stephan Windecker

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Scott Berry

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Presenter: Dean J. Kereiakes, Pieter C. Smits

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Stuart J. Pocock

October 30, 2016

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Advertisement

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Levels of Evidence: Single-center vs Multicenter Trials

Have Contemporary DES Narrowed the Gap With CABG in Multivessel Disease? From BEST to SYNTAX II and Beyond

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Comparative DES Outcomes: What Have We Learned From the SCAAR Registry? Update on Recent New Generation DES

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Stent Design and Comprehensive Data Review: From Nobori to Ultimaster Biolimus-Eluting Stents

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Stent Design and Comprehensive Data Review: BioMatrix Biolimus-Eluting Stents

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content